Maackiain Modulates miR-374a/GADD45A Axis to Inhibit Triple-Negative Breast Cancer Initiation and Progression

Fu Peng1, Li Wang1, Liang Xiong2, Hailin Tang3, Junrong Du1* and Cheng Peng2*

1Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China, 2State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 3Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

Breast cancer ranks as the leading cause of death in lethal malignancies among women worldwide, with a sharp increase of incidence since 2008. Triple negative breast cancer (TNBC) gives rise to the largest proportion in breast cancer-related deaths because of its aggressive growth and rapid metastasis. Hence, searching for promising targets and innovative approaches is indispensable for the TNBC treatment. Maackiain (MA), a natural compound with multiple biological activities, could be isolated from different Chinese herbs, such as Spatholobus suberectus and Sophora flavescens. It was the first time to report the anti-cancer effect of MA in TNBC. MA could suppress TNBC cell proliferation, foci formation, migration, and invasion. MA also exerted a significant inhibitory effect on tumor growth of TNBC. Furthermore, MA could induce apoptosis with an increase of GADD45α and a decrease of miR-374a. In contrast, overexpressing miR-374a would result in at least partly affecting the proapoptotic effect of MA and suppressing GADD45α stimulated by MA. These results reveal the anti-TNBC effect of MA in vitro and in vivo, providing evidence for its potential as a drug candidate utilized in TNBC therapy.

Keywords: triple negative breast cancer, maackiain, miR-374a, GADD45α, EMT—epithelial to mesenchymal transformation

INTRODUCTION

In 2020, breast cancer still ranked as the leading cause of death in cancer-related female patients worldwide, with the highest incidence (47.8 per 100,000 population) and the second highest mortality (13.6 per 100,000 population) based on the data from the Global Cancer Observatory database (An et al., 2021). According to molecular profiling, breast cancer is a complicated disease including various molecular subtypes, namely, luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and triple-negative (Sinha et al., 2013). Approximately 15% of diagnosed breast cancers are triple negative breast cancer (TNBC), exerting higher recurrence, more aggressive growth, and more rapid metastasis (Tang et al., 2019). TNBC patients do not respond to hormone therapy or HER2 targeted agents because TNBC is the absence of hormone-receptor and HER2. Thus, it is urgent to search for novel targets and approaches to rise to the TNBC clinical challenge.
MicroRNAs (miRNAs) are classified as a class of small non-coding RNA molecules of 20-22 nucleotides negatively regulating their targets through cleavage or translational repression (Mendell et al., 2012). MiRNAs modulate diverse cellular processes relying on the impressive regulatory function even in cancer. The first study exploring the role of miRNAs in breast cancer was reported in 2005. The findings indicated overexpressed miR-21 and miR-155 in breast cancer patients as oncogenic gene (Iorio et al., 2005). Since then, a substantial number of studies started to focus on this novel conserved non-coding RNA in breast cancer management. Recently, it was pointed out that miR-374a could induce tumorigenicity and progression of breast cancer through the deregulation of β-lactamases, which was detected as part of the mitochondrial ribosomal complex (Zhang et al., 2018). Additionally, in TNBC, miR-374a promoted cancer development by directly targeting arrestin β1, a member of the arrestin/β-arrestin family (Son et al., 2019). These reports suggested miR-374a as an oncogene in breast cancer. Therefore, it is worthwhile to expand the underlying mechanism of miR-374a regulation and discover approaches to suppress miR-374a in TNBC. *Spatholobus suberectus* Dunn (*S. suberectus*), a traditional Chinese medicine (TCM), could promote blood circulation and remove blood stasis according to TCM theory, implying its function to treat blood-stasis related diseases. *S. suberectus* was commonly used to treat rheumatism, anemia, and menoxenia in clinic (Qin et al., 2019). *S. suberectus* has been shown to have diverse pharmacological properties including anti-inflammatory, anti-bacterial, antioxidant, and antidiabetic effects (Fu et al., 2017; Do et al., 2018; Guo et al., 2018). Especially, *S. suberectus* treatment displayed cytotoxicity in myeloma cells and leukemia cells by promoting reactive oxygen species stress and inducing apoptosis (Lim et al., 2019). Recent studies declared that *S. suberectus* manifested an inhibitory effect on breast cancer via arresting the cell cycle and declining lactate dehydrogenase (Wang et al., 2013). *S. suberectus* could also inhibit TNBC *in vitro* and *in vivo* through ROS-induced pyroptosis (Zhang et al., 2021). Interestingly, pure compounds isolated from it also possessed potent anti-cancer effects in breast cancer according to our previous study (Peng et al., 2019). Maackiain (MA, Figure 1) could be extracted from *S. suberectus*, *Sophora flavescens*, and many other Chinese herbal medicines (Tsai et al., 2020). MA exerted multiple pharmacologic activities, such as anti-allergic, anti-cancer, and anti-inflammatory effects (Aratanechemuge et al., 2004; Mizuguchi et al., 2015). Accordingly, it is interesting to explore the inhibitory capacity of MA on TNBC as a promising drug candidate.

In this study, it is the first report to declare the anti-cancer propriety of MA in TNBC. MA exhibits a significant repressive impact on TNBC cell proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion. MA also blocks foci formation and tumor growth of TNBC. In addition, MA could promote growth arrest and DNA damage-inducible 45α (GADD45α) protein as well as miRNA expression through the downregulation of miR-374a, resulting in a proapoptotic consequence. Conversely, overexpressed miR-374a could at least partly reverse the apoptosis-inducing capacity of MA and decrease GADD45α expression induced by MA. Taken together, our work indicates MA is a promising anti-TNBC agent owing to its ability to modulate miR-374a.

**MATERIALS AND METHODS**

**Chemicals and Reagents**

Reagents utilized in this study were obtained from typical companies. Specifically, the purity of MA reached 98% and was purchased from Chem Faces (Wuhan, China). The stacking solution of MA was dissolved in DMSO. When using MA to treat TNBC cells, the stacking solution was diluted until the percentage of DMSO was below 0.1%. Xylene, Eosin Y, Hematoxylin, and others were also purchased from typical companies such as Sigma (St. Louis, MO).

**Cell Culture**

TNBC cell line MDA-MB-231 and BT549 from American Type Culture Collection (ATCC, United States) were incubated in a 5% CO2 37°C incubator. A total of 293 T cells was also obtained from ATCC. FBS was obtained from Gibco (Life Technologies, United States). All the mediums, penicillin, and trypsin were obtained from Hyclone (Cytiva, United States). MDA-MB-231, BT549, and 293 T were cultured in DMEM medium. When culturing cells, 10% FBS, 1% penicillin, and 1% streptomycin were added in cell medium.

**CCK-8 Assay**

TNBC cells were seeded in the 96 well plates at a concentration of 5×10^4 cells/ml treated with different doses (0, 2.5, 5, 10, 20, 40, 80, 100 μM) of MA for 24 and 48 h. After MA treatment, 10 μL CCK-8 reagents were added to the 96 well plates according to the manufacturer’s instructions (MedChemExpress, United States). After incubation, the absorbance would be read by an ELISA plate reader at 450 nm. Triplicate experiments were performed independently.

**Foci Formation Assay**

Foci formation assay would be conducted as previously (Peng et al., 2020). Briefly, clones were stained with 0.5% crystal violet for 15 min. Foci numbers were counted after staining. Triplicate experiments were performed independently.
Flow Cytometry Analysis
Flow cytometry analysis would be conducted as previously (Peng et al., 2020). Briefly, FITC-conjugated Annexin V and PI staining were conducted through apoptosis analysis kit (BD Company, CA). After washing TNBC cells with cold PBS, the cells were resuspended in 1 × binding buffer at the concentration of 1 × 10^6 cells/ml. Then, we gently mixed cells with Annexin V and PI for 15 min at room temperature in the dark. Finally, stained cells were analyzed by flow cytometry within 1 h. Triplicate experiments were performed independently.

Chamber Invasion Assays
To determine the effect of MA on TNBC cell invasion, 6-well transwell chambers with Matrigel were utilized (Coring, United States). TNBC cells were planted at the upper compartment of the transwell plates at a concentration of 2.5×10^5 cells/well. After being treated with MA (0, 1 μM, 2.5 μM, 5 μM) for 24 h, invading cells were stained through 0.5% crystal violet. The remaining cells were detected through microscope (ZEISS, Germany).

Wound Scratch Assay
Wound scratch assays were performed as previously (Gong et al., 2018). Briefly, 3×10^5 cells/ml of TNBC cells were plated into Culture-Insert (ibidi GmbH, Martinsried, Germany). After 24 h cell attachment, Culture-Insert was gently removed. After MA treatment (0, 1, 2.5 and 5 μM) for another 24 h, scratches were recorded at the beginning and the end point of the experiment through microscope (ZEISS, Germany).

Western Blot
The protein in TNBC cells was extracted using cell lysis buffer (St. Louis, MO). There was 20-30 μg protein resolved on 10% SDS-PAGE gels and transferred onto PVDF membrane (Millipore, Merck, United States). We incubated sliced membranes and primary antibody against E-cadherin, N-cadherin, Vimentin, α-actin or GAPDH was selected as the loading control. After incubating sliced membranes and secondary antibody for 1 h, the detection was conducted via ECL Advance Reagent (Millipore, Merck, United States) and Image Lab Software (Bio-rad, Kidlington, UK).

Quantitative Real-Time PCR
We extracted total RNA via RNAiso Plus (Takara, Shiga, Japan) reagent after exposure to MA for 24 h. The RNA transcription into cDNA was performed via PrimeScript RT Reagent Kit with gDNA Eraser (Takara, Shiga, Japan). The real-time PCR for amplification was conducted through TB Green (Takara, Shiga, Japan). MiRNA was extracted through miRNeasy Mini Kit from Qiagen (Germany) after treatment. The miRNA transcription into cDNA was performed via TaqMan MicroRNA Reverse Transcription Kit (Ambion, Life Technologies, United States). The real-time PCR for amplification was conducted through ExiLENT SYBR Green master mix (QIAGEN, United States). GAPDH and U6 were selected as the loading control, and 2^−ΔΔCT values were calculated. The following primers utilized for real time PCR were listed in Supplementary Table S1.

PCR Array
PCR assay was performed via microRNA PCR Panel (Qiagen, Germany) as previously described (Peng et al., 2020). Briefly, miRNA in TNBC cells was extracted using miRNeasy Mini Kit from Qiagen (Germany) in different groups. We used TaqMan MicroRNA Reverse Transcription Kit from Ambion (Life Technologies, United States) to conduct miRNA transcription. We conducted real-time PCR for amplification corresponding cDNA using ExiLENT SYBR Green master mix.

Cell Transfection
MirVana miRNA-374a mimic and mirVana miRNA mimic Negative Control were purchased from Ambion (Life Technologies, United States). We chose Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, Life Technologies, United States) as transfection reagent. TNBC cells were plated on 6 well plates at a concentration of 2.5×10^5 cells/ml. The complexes of miRNA and transfection reagent were added to TNBC cells. Then, the plates were incubated at 37°C in the cell incubator for at least 24 h.

Luciferase Reporter Assay
The pMIR-REPOR miRNA Expression Reporter Vector System and Dual-Glo luciferase Assay System (Promega, Madison, WI) were utilized to verify the interaction between miR-374a and 3′UTR region of GADD45A. There are five groups, including the control group, miRNA mimic negative control + GADD45A 3′UTR wild type, miRNA-374a mimic + GADD45A 3′UTR wild type, miRNA mimic negative control + GADD45A 3′UTR mutated, and miRNA-374a mimic + GADD45A 3′UTR mutated. The reagents were added based on the manufacturer’s instruction. The luciferase activity was recorded by SpectraMax M5. The primers for amplification are shown in Supplementary Table S2.

Xenograft Tumor Growth Assays
Concisely, we conducted cell injection with 2×10^6 MDA-MB-231 cells into the dorsal flanks to establish a TNBC xenograft tumor model. After model establishment, 4-week-old nude mice were separated into the control group, low dose group (MA, 25 mg/kg/d), and high dose group (MA, 50 mg/kg/d) randomly (n = 10). We administered MA to mice through intraperitoneal injection for 28 days with a record of tumor volumes. After 28 days administration, mice were sacrificed and tumor weights were assessed. The animal experiments were conducted complying with the institutional guidelines of Sichuan University and Chengdu University of Traditional Chinese Medicine.

Immunohistochemistry
Immunohistochemistry (IHC) was utilized to detect GADD45a protein distribution and expression in tumor tissues. Tumor bulks
were collected after nude mice were sacrificed at the end point of the animal study. The tumor tissues were deparaffinized and rehydrated, before antigen retrieval with sodium citrate 10 mM, pH 6.0 at a high temperature. Before slides were incubated with the primary antibody against GADD45α (Cell Signaling, Danvers, MA), the section was blocked in 5% goat serum for 1 h at room temperature. After rinsing with TBST three times, we incubated the slides with HRP secondary conjugates for 30 min at room temperature. SignalStain DAB Substrate Kit was adopted to determine GADD45α protein in tumor tissues. We used hematoxylin to stain the nuclei. The results were recorded through a Zeiss microscope Axio Lab A1.

**Data Analysis**

We utilized GraphPad Prism 7.0 (Graph Pad Software, San Diego, CA) to conduct analyzing and visualizing data. The corresponding data were present as means ± standard deviations (SD). We used two-tailed student’s test and one-way ANOVA to assess the statistical significance of data (*p < 0.05, **p < 0.01, ***p < 0.01).

**FIGURE 2** MA attenuates TNBC cell growth. 
(A) Cell viability of TNBC cells after MA treatment. (B) Representative images and number of foci formation in TNBC cells after exposure to MA for 24 h. Compared with the control group (0 μM), *p < 0.05, **p < 0.01.
RESULTS

MA Exerts Cytotoxic Effects on TNBC Cells

To assess the inhibitory effect of MA on TNBC proliferation, we used a CCK-8 assay. After 24 h MA treatment, the cell viability was notably repressed above the concentration of 10 μM in BT549 and MDA-MB-231 cells. The IC50 values of MDA-MB-231 and BT549 cells were 25.24 and 20.99 μM, respectively (Supplementary Figure S1). MA could inhibit TNBC cell proliferation remarkably at the concentration of 5 μM for 48 h.
treatment ($p < 0.01$). In the meantime, MA demonstrated a dose-dependent suppression of cell viability in TNBC cells ($p < 0.01$) (Figure 2A). The cytotoxic effect of MA on TNBC cells was further determined via foci formation assay. As shown in Figure 2B, MA could reduce the number of foci in MDA-MB-231 and BT549 cells after 24 h inference. Taken conjointly, MA has a repressive effect on TNBC cell growth and foci formation.

**MA Promotes Apoptosis in TNBC Cells**

The results of Annexin V/PI staining apoptosis analysis showed that MA could induce an increase of a percentage of apoptotic cells after 24 h interference in TNBC cells ($p < 0.01$) (Figure 2A). The increasing percentage of apoptotic cells was consistent with the increasing of MA concentration. Additionally, MA could enhance Bax protein expression and reduce Bcl-2 protein expression (Figure 3B). Bax promotes mitochondrial apoptosis as a proapoptotic factor, while Bcl-2 restrains apoptosis progress as an anti-apoptotic factor. Meanwhile, MA could upregulate Bax mRNA expression and downregulate Bcl-2 mRNA expression (Figure 3C). These data signify that MA might inhibit TNBC cell proliferation by triggering mitochondrial-based apoptosis.

**MA Inhibits EMT in TNBC Cells**

Based on the data from the CCK-8 assay, MA could not affect cell proliferation of BT549 and MDA-MB-231 cells under the concentration of 5 μM for 24 h treatment. Thus, we adopted 0, 1, 2.5, and 5 μM MA to conduct the study further about the suppressive effect of MA on TNBC cell mobile capacity. Wound healing assay exerted that after MA treatment for 24 h, the percentages of BT549 and MDA-MB-231 cells to moving into the wound area were significantly repressed, compared with the control group (Figure 4A). Similarly, invading cell numbers were dramatically abated after MA treatment for 24 h according to the results of a chamber invasion assay (Figure 4B). The EMT process plays an essential role in cancer cell migration and invasion. Mesenchymal phenotype markers (N-cadherin, Vimentin) protein expression was remarkably decreased, while epithelial phenotype marker (E-cadherin) protein expression was noticeably increased after MA interference in TNBC cells (Figure 4C). Meanwhile, MA-treated cells manifested a significant increase of E-cadherin mRNA (Figure 4D). These findings thus imply that MA hinders EMT progression to successively hamper the migratory and invasive abilities of TNBC cells.

**MA Suppresses TNBC Tumor Growth**

To investigate the suppressive effect of MA in vivo, MDA-MB-231 cells were injected into mammary fat pads of 4-week-old nude mice. After 28 days MA intraperitoneal injection, the mice were sacrificed, and the tumors were collected. The volumes and weights of tumors were recorded and compared. The results displayed that MA could reduce the volume and weights of tumors compared to the control group, and the high-dose group had a significantly more inhibitory effect on tumor growth than the low-dose group (Figures 5A–C). Interestingly, even the high dose of MA did not affect the body weights significantly compared to the control group (Figure 5E). HE staining demonstrated that in the control group, there were a large number of agglomerated and closely arranged tumor cells with deeply stained nuclei. In MA-treated groups, especially the high-dose group, the number of tumor cells decreased dramatically and the arrangement was relatively loose (Figure 5F). Taken together, MA also has a critical inhibitory effect on TNBC tumor growth in vivo.

**MA Downregulates Overexpressed miR-374a in TNBC Cells**

Accumulating evidence indicates that miRNAs play an essential role in cell proliferation and tumor growth in breast cancer. A PCR array was performed to screen the varied miRNA with at least 1.5-fold change after MA treatment. According to the results, miR-374a was notably abated in both cell lines after exposure to 20 μM MA for 24 h (Figure 6A). According to the clinical data from the dbDEMC database (https://www.biosino.org/dbDEMC/index), miR-374a was highly expressed in various cancers compared to their corresponding normal tissues, suggesting miR-374a as an oncogene (Figure 6B) (Yang et al., 2017). Besides, miR-374a was confirmed to express at a high level in basal-like breast cancer tissues (Supplementary Figure S2). Also, data from the TCGA database using UALCAN analysis (http://ualcan.path.uab.edu/analysis.html) showed that miR-374a was dramatically overexpressed in TNBC tissues compared to other molecular types of breast cancer (Figure 6C) (Chandrashekar et al., 2017). Utilizing real-time PCR, we confirmed that MA had an inhibitory effect on miR-374a of TNBC cells in a dose-dependent manner (Figure 6D). Collectively, these data manifest that MA inhibits oncogenic miR-374a in TNBC cells.

**MA Modulates miR-374a/GADD45α Axis**

DIANA TOOLS (http://diana.imis.athena-innovation.gr/DianaTools/) predicted that GADD45α was one of the most potential targets of miR-374a (Supplementary Figure S3), and a present study suggested GADD45α as the downstream of miR-374a in a pheochromocytoma cell (Gong et al., 2018). Dual luciferase reporter assay confirmed that miR-374a could directly bind to the 3′UTR region of GADD45α (Figure 6E). Based on the data from the TCGA database using UALCAN analysis, GADD45α was locally expressed in various types of cancer, including breast cancer. Moreover, GADD45α was dramatically expressed at a low level in TNBC, compared to normal tissues (Figures 7A,B). Pathway common (https://www.pathwaycommons.org/) exerted genes interacting with GADD45α (Supplementary Table S3) and KEGG annotation classification statistics of these genes indicated their role in cancer as well as MAPK pathway (Figures 7C,D). Further study displayed that MA could facilitate GADD45α mRNA and protein levels dose-dependently after 24 h treatment (Figures 8A,B). The in vivo results were inconsistent with in vitro findings. Determined by IHC staining, GADD45α was almost absent in tumor tissue and significantly increased in the MA high-dose group (Figure 5F). Results from real-time PCR exerted that
FIGURE 4 | MA alleviates migration and invasion of TNBC cells. (A) Representative images of wound healing assay and healing percentage of TNBC cells after 24 h MA treatment. (B) Representative images of chamber invasion assay and number of invading cells after 24 h MA treatment. (C) Western blot analysis of EMT-related protein levels after 24 h MA intervention. (D) Real-time PCR analysis of E-cadherin after exposure to MA for 24 h. Compared with the control group (0 μM), *p < 0.05, **p < 0.01.
FIGURE 5 | MA restrains TNBC tumor growth. (A) Collected tumor tissues after MA administration. (B) Tumor volumes in different groups during the experiment. (C) Tumor weights in different groups after MA administration. (D) Real-time PCR analysis of GADD45α mRNA levels in xenograft models at the end point. (E) Body weights of mice in different groups during the experiment. (F) Representative images of HE staining and IHC analysis of GADD45α after MA administration. Compared to the control group, **p < 0.01; compared to the low-dose group, ##p < 0.01.
FIGURE 6 | Overexpressed miR-374a is inhibited by MA in TNBC cells. **(A)** PCR array analysis of miRNAs variation in TNBC cells after 24 h MA intervention. **(B)** miR-374a expression in different types of cancer tissues and the corresponding normal tissues. **(C)** miR-374a expression in different types of breast cancer tissues and normal tissues. **(D)** Real-time PCR analysis of miR-374a expression in TNBC cells after 24 h MA intervention. **(E)** Relative luciferase activity determined through dual luciferase reporter assay in 293 T cells. Compared to the control group, **p < 0.01.**
GADD45A was lowly expressed in tumor tissues, and MA treatment could enhance GADD45A expression dose-dependently in vivo (Figure 5D). To evaluate the effect of miR-374a downregulated by MA on GADD45A, we transfected BT-549 and MDA-MB-231 cells with miRNA mimic negative control and miR-374a mimic, and the successful transfection was confirmed by real-time PCR (Figure 8C). GADD45α mRNA and protein expression were
detected after miR-374a mimic transfection and MA treatment. As shown in Figures 8D,E, MA could significantly promote GADD45α mRNA and protein levels at the concentration of 20 μM, and the effect was at least partly blocked after the miR-374a mimic pretreatment. Besides, Western blot results demonstrated that MA could promote Bax expression, and the upregulation of miR-374a would at least partly reverse the effect of MA (Figure 8F). As for BAX mRNA expression, the miR-374a mimic exerted a similar effect even after MA treatment (Figure 8G). Altogether, MA might activate GADD45α and related genes through downregulation of miR-374a in TNBC cells.

**DISCUSSION**

Breast cancer is the most common cancer occurring in women worldwide, with increasing incidence. TNBC belongs to the most...
aggressive subtype of breast cancer, always accompanying worse clinical outcome (Feng Wang et al., 2021). Despite improvement in breast cancer therapeutic measures, the treatment for TNBC clinically without obvious side effects is still a huge challenge (Ghosh et al., 2021). Searching for complementary and alternative medicine is critical for the advancement of current TNBC therapies. Presently, TCM, with multiple biological capacities, gains credibility and reputation as a source of potential anti-cancer reagents (Yao et al., 2021). According to our previous work, several pure compounds isolated from S. suberectus could inhibit breast cancer (Peng et al., 2020; Peng et al., 2021b). We found that MA, extracted from S. suberectus, could also suppress the proliferative, migratory, and invasive abilities of TNBC cells (Figures 2, 3, 4). Apart from in vitro study, results from animal experiments further confirmed its anti-TNBC effect (Figure 5). Consequently, our study first clarified the anti-breast cancer property of MA. Meanwhile, it is interesting that we found that MA could downregulate miR-374a (Figure 6), an oncogenic regulator in TNBC cells promoting cell proliferation, migration, and invasion (Cai et al., 2013; Du et al., 2019; Son et al., 2019).

Triggering apoptosis relied on the balance between prosurvival and proapoptotic BCL-2 protein family members (Diepstraten et al., 2021). A recent study pointed out that DNA damage and oncogene deregulation could contribute to the activation of BCL-2 family-regulated pathway (Singh et al., 2019). Interestingly, miR-374a could act as an oncogenic factor in various types of cancer, and the down-regulation of miR-374a frequently led to stimulating apoptosis (Peng et al., 2021a). Our study exerted the proapoptotic effect of MA with a decrease of miR-374a, and miR-374a could directly bind to the 3′UTR region of GADD45A (Figures 8, 5, 6). GADD45A belongs to the growth arrest and DNA damage-inducible 45 family, mainly affecting cell cycle and interacting with cell growth modulators (Sytnikova et al., 2011). Furthermore, GADD45A had an inhibitory effect on cell cycle and cell proliferation through the regulation of P53 in bladder cancer (Han et al., 2019). More recent studies indicated GADD45A could even act as a tumor suppressive gene by facilitating apoptosis, maintaining cell-to-cell adhesion, inhibiting angiogenesis, modulating drug resistance, suppressing metastasis, promoting DNA repair, and stabilizing genomics (Yang et al., 2013; Bartoszewski et al., 2020; Runtian Wang et al., 2021). GADD45A was gradually considered as a promising target for tumor malignancy (Lin et al., 2022). More recent studies made an effort to prove that natural compounds could promote apoptosis through the activation of the cellular function of GADD45A (Jang et al., 2021). Meanwhile, MA could upregulate both GADD45a protein and mRNA expression, and overexpressing miR-374a would at least partly block the effect (Figure 8). These findings suggested the modulatory effect of MA in the mitochondria apoptotic signaling with the function to promote GADD45A through the inhibition of miR-374a in TNBC.

In addition to accelerating tumor growth, miR-374a is attributed to epithelial cells shifting into mesenchymal stem cells, namely, EMT process in cancer (Ma et al., 2019). In cancer cells, EMT initiates migration and invasion with the increase of more aggressive capacities (Bakir et al., 2020). EMT initiation is based on

E-conifer along with N-cadherin switch, resulting in lessening cell-cell adhesion and gaining mobile ability (Biswas, 2020). Intriguingly, MA could upregulate E-cadherin and downregulate N-cadherin, accompanying a decrease of migratory and invasive TNBC cell numbers (Figure 4). In the meantime, MA could diminish miR-374a expression (Figure 6). These data first implied the role of MA as the mediator of the EMT process in TNBC cells.

CONCLUSION

TNBC cells tend to be more aggressive and EMT-activated than other molecular types of breast cancer. Our study demonstrated that MA had an inhibitory effect on TNBC proliferation, migration, invasion, and tumor growth as a promising drug candidate. Interestingly, MA could significantly repress miR-374a, which was usually considered as an oncogene regulating cancer initiation and development. Moreover, MA could promote GADD45a protein and mRNA expression through the downregulation of miR-374a. Further study confirmed that miR-374a directly targeted the 3′UTR region of GADD45A. Furthermore, the proapoptotic effect of MA was also negatively correlated to the expression of miR-374a. These findings first reported the anti-breast cancer effect of MA, pointed out GADD45A as the direct target of miR-374a in breast cancer, and partly offered evidence for S. suberectus as a resource of novel drug candidates in TNBC therapy.

DATA AVAILABILITY STATEMENT

Datasets generated for this article can be found in [TCGA] using the accession number TCGA-BRCA. The data are analyzed using UALCAN (http://ualcan.path.uab.edu/analysis.html).

ETHICS STATEMENT

The animal study was reviewed and approved by Ethics Committee of Chengdu University of Traditional Chinese Medicine.

AUTHOR CONTRIBUTIONS

The study was designed by FP and CP. The manuscript was written by FP and LW. FP performed experiments and analyzed data with LX and HT. LX and HT revised the manuscript. CP and JD supported the study.

FUNDING

The study was supported by National Natural Science Foundation of China (no. 82003879 and and U19A2010), the Key Project of Science and Technology Department of Sichuan Province (no. 2020YFS0053), and Youth Talent Promotion Project of China.
Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.806869/full#supplementary-material
Tang, Q., Ouyang, H., He, D., Yu, C., and Tang, G. (2019). MicroRNA-Based Potential Diagnostic, Prognostic and Therapeutic Applications in Triple-Negative Breast Cancer. *Artif. Cell Nanomed. Biotechnol.* 47, 2800–2809. doi:10.1080/21691401.2019.1638791

Tsai, R.-T., Tsai, C.-W., Liu, S.-P., Gao, J.-X., Kuo, Y.-H., Chao, P.-M., et al. (2020). Maackiai Ameliorates 6-Hydroxydopamine and SNCA Pathologies by Modulating the PINK1/Parkin Pathway in Models of Parkinson’s Disease in *Caenorhabditis elegans* and the SH-SY5Y Cell Line. *Ijms* 21, 4455. doi:10.3390/ijms21124455

Wang, Z., Wang, D., Han, S., Wang, N., Mo, F., Loo, T. Y., et al. (2013). Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus Suberectus on Breast Cancer. *PLoS One* 8, e56631. doi:10.1371/journal.pone.0056631

Yang, F., Zhang, W., Li, D., and Zhan, Q. (2013). Gadd45a Suppresses Tumor Angiogenesis via Inhibition of the mTOR/STAT3 Protein Pathway. *J. Biol. Chem.* 288, 6552–6560. doi:10.1074/jbc.M112.418335

Yang, Z., Wu, L., Wang, A., Tang, W., Zhao, Y., Zhao, H., et al. (2017), dbDEMC 2.0: Updated Database of Differentially Expressed miRNAs in Human Cancers. *Nucleic Acids Res.* 45, D812–D818. doi:10.1093/nar/gkw1079

Yao, C. L., Zhang, J. Q., Li, J. Y., Wei, W. L., Wu, S. F., and Guo, D. A. (2021). Traditional Chinese Medicine (TCM) as a Source of New Anticancer Drugs. *Nat. Prod. Rep.* 38, 1618–1633. doi:10.1039/d0np00057d

Zhang, J., He, Y., Yu, Y., Chen, X., Cui, G., Wang, W., et al. (2018). Upregulation of miR-374a Promotes Tumor Metastasis and Progression by Downregulating LACTB and Predicts Unfavorable Prognosis in Breast Cancer. *Cancer Med.* 7, 3351–3362. doi:10.1002/cam4.1576

Zhang, F., Liu, Q., Ganesan, K., Kewu, Z., Shen, J., Gang, F., et al. (2021). The Antitriple Negative Breast Cancer Efficacy of Spatholobus Suberectus Dunn on ROS-Induced Noncanonical Inflammasome Pyroptotic Pathway. *Oxid Med. Cell Longev* 2021, 5187569. doi:10.1155/2021/5187569

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.